| |
Gardasil in Older Women Aged 24-45 yrs old
|
| |
| |
"The quadrivalent HPV vaccine is efficacious in women aged 24-45 years not infected with the relevant HPV types at enrolment."
Gardasil in Older Women Aged 24-45 Years
Jun 2, 2009 ... Studies of the natural history of human papillomavirus (HPV) ... Recent phase III trials (FUTURE I and II) undertaken in about 15 000 women ...
www.natap.org/2009/HIV/060409_01.htm
"In the per-protocol population, efficacy against the first coprimary endpoint (disease or infection related to HPV 6, 11, 16, and 18) was 90·5% (95% CI 73·7-97·5, four of 1615 cases in the vaccine group vs 41/1607 in the placebo group) and 83·1% (50·6-95·8, four of 1601 cases vs 23/1579 cases) against the second coprimary endpoint (disease or infection related to HPV 16 and 18 alone). In the intention-to-treat population, efficacy against the first coprimary endpoint was 30·9% (95% CI 11·1-46·5, 108/1886 cases vs 154/1883 cases) and against the second coprimary endpoint was 22·6% (-2·9 to 41·9, 90/1886 cases vs 115/1883 cases), since infection and disease were present at baseline. We recorded no vaccine-related serious adverse events."
| |
| |
| |
|
|
|
